Loading…
Loading…
On September 01, 2026, Stevanato Group SpA (STVN) shares fell 3.4% to a current price of $20.71, trading within a 52-week range of $12.89 to $28.00. This recent
Stevanato Group is transforming from a pharmaceutical glass supplier into an integrated drug containment and delivery platform, validated by commercial adoption of its Alina injector. High-value solutions now drive 45% of revenue, growing 16% year-over-year, with recent capacity investments in Fishers and Latina expected to boost operating leverage and margin expansion. STVN is shifting its portfolio toward premium, integrated offerings, divesting low-margin assets like Balda and focusing on durable, higher-margin customer relationships.
On August 28, 2026, Stevanato Group SpA (STVN) shares fell 5.7%, closing at $21.03. The stock has experienced a volatile year, with a 52-week range of $12.89 to
Stevanato Group (NYSE: STVN) reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary. Revenue for the quarter reached €302 million, up 8% both on a reported and constant-currency
Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.
Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago.